<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3195">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01928901</url>
  </required_header>
  <id_info>
    <org_study_id>Saccharin test</org_study_id>
    <nct_id>NCT01928901</nct_id>
  </id_info>
  <brief_title>Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)</brief_title>
  <official_title>Randomized, Placebo-controlled, Double-blind, Cross-over Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bionorica SE</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bionorica SE</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of concept: Superiority of Bronchipret or Sinupret to placebo in respect to
      mucociliary clearance
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Time to perception of sweetness</measure>
    <time_frame>after 7 days of treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to perception of sweetness after 7 days of treatment with the investigational products - relative to the time to perception of sweetness at the begin-ning of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perception of Sweetness of Saccharin</measure>
    <time_frame>4 - 7 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To measure the time to perception of sweetness of Saccharin after 7 days of treatment with the investigational products calculated as difference to time to perception of sweetness at the beginning of treatment. The time of sweetness will be measured in minutes and seconds.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Current Smokers</condition>
  <arm_group>
    <arm_group_label>administration of Bronchipret</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days of administration of Bronchipret, 2 FCT t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>administration of Sinupret</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 days of administration of Sinupret, 2 CT t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>administration of Bronchipret Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days of administration of Bronchipret Placebo, 2 FCT t.i.d</description>
  </arm_group>
  <arm_group>
    <arm_group_label>administration of Sinupret Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>7 days of administration of Sinupret Placebo, 2 CT t.i.d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of Sinupret</intervention_name>
    <arm_group_label>administration of Sinupret</arm_group_label>
    <arm_group_label>administration of Sinupret Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of Bronchipret</intervention_name>
    <arm_group_label>administration of Bronchipret</arm_group_label>
    <arm_group_label>administration of Bronchipret Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of Sinupret Placebo</intervention_name>
    <arm_group_label>administration of Sinupret</arm_group_label>
    <arm_group_label>administration of Sinupret Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>administration of Bronchipret Placebo</intervention_name>
    <arm_group_label>administration of Bronchipret</arm_group_label>
    <arm_group_label>administration of Bronchipret Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Volunteers who have given their signed declaration of consent and have signed the
             data protection declaration

          2. Male or female volunteers 25 - 40 years

          3. Current smokers (5-20 cigarettes per day since 5 years at least)

          4. Ability to taste sweetness of saccharin

          5. Perception of sweetness within 30 minutes after placement of saccharin behind nasal
             valve

        Exclusion Criteria:

          1. Ciliary dyskinesia

          2. Cystic fibrosis

          3. COPD/emphysema

          4. Asthma

          5. Chronic rhinosinusitis

          6. Acute respiratory tract infection within the last 6 weeks prior to enrolment

          7. Septal or sinus surgery

          8. Symptomatic allergic rhinitis

          9. Known allergic rhinitis

         10. Treatment with not-permitted previous or concomitant therapy

         11. History of snuff consumption for longer than 1 month or intranasal consumption of
             recreational drugs such as cocaine or heroin for longer than 1 month

         12. Any disease or condition that might affect the safety of the subject during the
             trial, according to the investigator's judgement
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claus Bachert, Prof.Dr.Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gudrun Werner</last_name>
    <phone>0049 9181231273</phone>
    <email>gudrun.werner@bionorica.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Bachert, Prof. Dr. Dr.</last_name>
      <email>Claus.Bachert@UGent.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 4, 2013</lastchanged_date>
  <firstreceived_date>August 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
